Embecta
Embecta's revenue fell 3.8% to $1.1 billion in fiscal 2025. Its operating margin was 22.4%, up from 14.8% a year earlier. Free cash flow was $182 million, up 816.6%. It paid out $35 million in dividends and buybacks, 19% of free cash flow. The diluted share count rose 1.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Embecta does
Embecta makes and sells devices for people with diabetes who inject insulin. Its products include pen needles, which attach to pen injectors that deliver insulin or other diabetes medicines, as well as syringes and safety injection devices. Its safety pen needles have shields that cover the needle after the injection to help prevent needlestick injuries.
It sells through pharmacies, wholesalers and other customers, and it says a substantial part of its revenue comes from a few of them. It competes with other makers of injection devices and with providers of insulin pumps. It separated from Becton, Dickinson and Company in 2022 and still buys the cannulas, the thin tubes in its needles, from that company.
Its fiscal year ends September 30. At the end of fiscal 2025 it had about 1,850 regular employees worldwide, with about 700 of them in the United States.
Its biggest risks, as it describes them
- A few key products produce much of its profits and cash flow.
- Advances in diabetes treatment or prevention could reduce demand for its products.
- A few customers account for a substantial part of its revenue.
- Problems in manufacturing or sterilizing its products could hurt its business.
Income statement
From fiscal 2020 to 2025, earnings per share fell 26.4% a year and net income 25.9% a year, as new shares raised the share count by 3% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 0 | 331 | 326 | 268 | 226 |
| Debt incl. finance leases | 0 | 1,644 | 1,638 | 1,608 | 1,430 |
| Net debt (negative means net cash) | 0 | 1,313 | 1,312 | 1,341 | 1,205 |
| Net debt to EBITDA | 0.0x | 3.9x | 5.2x | 6.6x | 4.3x |
| Debt to equity | 0.0x | — | — | — | — |
| Interest coverage | — | 8.0x | 2.0x | 1.4x | 2.3x |
| Current ratio | 1.8x | 2.2x | 2.1x | 2.0x | 2.4x |
| Quick ratio | 1.1x | 1.8x | 1.7x | 1.6x | 1.7x |
Cash flow
Projections
Project Embecta's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $557,850 of Embecta shares on the open market, and 1 insider sold $37,003.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 4, 2026 | Milton Mayo MorrisDirector | Sold | 6,293 | $5.88 | $37,003 | Form 4 |
| Aug 12, 2026 | Robert J. HombachDirector | Bought | 45,000 | $4.97 | $223,650 | Form 4 |
| Aug 12, 2026 | Devdatt KurdikarPresident and CEO, Director | Bought | 30,000 | $4.70 | $141,000 | Form 4 |
| Aug 12, 2026 | Jeffrey Z MannPres, Pharm Svc&Prod Mgmt, CLO | Bought | 20,000 | $4.99 | $99,800 | Form 4 |
| Aug 12, 2026 | Jacob ElguiczeSVP and CFO | Bought | 20,000 | $4.67 | $93,400 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 3 of 9 | 6 of 9 |
| Rule of 40 | 2.9% | 2.0% | 13.1% |
| Altman Z'' | 1.49 | 1.20 | 1.99 |
| Accruals ratio | 0.2% | 3.4% | −8.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Fail | Fail | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | 3 of 9 | 3 of 9 | 6 of 9 |
Compare
Put Embecta side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Embecta | FY25 | −3.8% | 22.4% | 16.9% | 29.3% | 4.3x | 6 | |
| Tandem Diabetes Care | FY25 | 7.9% | −18.4% | −2.9% | −85.5% | — | 4 | Compare |
| Stevanato Group S.p.A. | FY25 | 7.5% | 16.8% | 1.9% | 8.3% | — | 6 | Compare |
| Inspire Medical Systems | FY25 | 13.6% | 5.6% | 8.6% | 14.2% | −4.8x | 5 | Compare |
| CONMED | FY25 | 5.2% | 7.5% | 11.0% | 3.7% | 5.1x | 6 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 1,086 | 1,165 | 1,130 | 1,121 | 1,123 | 1,080 |
| Revenue growth | — | 7.3% | −3.1% | −0.8% | 0.2% | −3.8% |
| Gross profit | 763 | 800 | 775 | 750 | 735 | 677 |
| Research and development | 61 | 63 | 67 | 85 | 79 | 37 |
| Operating income | 486 | 492 | 310 | 222 | 167 | 242 |
| Net income | 428 | 415 | 224 | 70 | 78 | 95 |
| Diluted EPS (US$) | 7.50 | 7.28 | 3.89 | 1.22 | 1.34 | 1.62 |
| Diluted shares (millions) | 57 | 57 | 58 | 58 | 58 | 59 |
| Cash flow | ||||||
| Cash from operations | 498 | 456 | 412 | 68 | 36 | 192 |
| Capital expenditure | 42 | 37 | 24 | 26 | 16 | 9 |
| Free cash flow | 457 | 420 | 389 | 41 | 20 | 182 |
| Dividends paid | 0 | 0 | 9 | 34 | 34 | 35 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 13 | 13 | 19 | 22 | 26 | 32 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 0 | 0 | 331 | 326 | 268 | 226 |
| Debt incl. finance leases | — | 0 | 1,644 | 1,638 | 1,608 | 1,430 |
| Total assets | — | 788 | 1,086 | 1,214 | 1,285 | 1,091 |
| Total liabilities | — | 194 | 1,978 | 2,036 | 2,024 | 1,742 |
| Shareholders' equity | 572 | 594 | −891 | −822 | −738 | −651 |
| Margins and ratios | ||||||
| Gross margin | 70.2% | 68.7% | 68.6% | 66.9% | 65.5% | 62.6% |
| Operating margin | 44.8% | 42.2% | 27.4% | 19.8% | 14.8% | 22.4% |
| Net margin | 39.4% | 35.6% | 19.8% | 6.3% | 7.0% | 8.8% |
| Free cash flow margin | 42.1% | 36.0% | 34.4% | 3.7% | 1.8% | 16.9% |
| Rule of 40 (growth + FCF margin) | — | 43.4% | 31.3% | 2.9% | 2.0% | 13.1% |
| Return on capital | — | — | 53.1% | 32.4% | 30.5% | 29.3% |
| Return on equity | — | — | — | — | — | — |
| Return on assets | — | — | 23.9% | 6.1% | 6.3% | 8.0% |
| Net debt to EBITDA | — | 0.0x | 3.9x | 5.2x | 6.6x | 4.3x |